Glaukos (NYSE:GKOS) is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions. Its iDose TR implant delivers a controlled release of travoprost directly into the eye over several months, aiming to reduce patient compliance issues associated with daily eye drops. Through its acquisition of Avedro in 2019, Glaukos also offers corneal cross-linking technologies and other phototherapeutic solutions for the treatment of keratoconus and corneal ectasia, broadening the company’s presence in the ophthalmic market.
Founded in 1998 and headquartered in San Clemente, California, Glaukos has built a global commercial organization serving surgeons and patients in North America, Europe, Asia Pacific and the Middle East. The company combines direct sales teams in key markets with strategic distribution partnerships to support product training, clinical research and market access. Glaukos continuously invests in research and development to advance its pipeline of minimally invasive ophthalmic therapies.
Leadership at Glaukos is headed by President and Chief Executive Officer Thomas Burns, who joined the company in 2018 and has overseen its expansion into new therapeutic areas and geographies. Under his guidance, Glaukos remains committed to improving patient outcomes through novel, less-invasive treatments that aim to preserve vision and enhance quality of life for individuals living with glaucoma and other eye diseases.
